Raymond James Downgrades Loxo Oncology (LOXO) to Market Perform Following Acquisition
Tweet
Share
E-mail
Get Alerts LOXO Hot Sheet
Price: $234.80 --0%
Rating Summary:
7 Buy, 8 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 12 | Down: 21 | New: 20
Rating Summary:
7 Buy, 8 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 12 | Down: 21 | New: 20
Join SI Premium – FREE
Raymond James analyst Dane Leone downgraded Loxo Oncology (NASDAQ: LOXO) from Strong Buy to Market Perform.
For an analyst ratings summary and ratings history on Loxo Oncology click here. For more ratings news on Loxo Oncology click here.
Shares of Loxo Oncology closed at $139.87 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- William Blair Downgrades Enovix Corporation (ENVX) to Market Perform
- Johnson Rice Downgrades Expand Energy (EXE) to Accumulate
- Deutsche Bank Downgrades Workday (WDAY) to Hold
Create E-mail Alert Related Categories
DowngradesRelated Entities
Raymond JamesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
